Schall Law Firm Targets Immutep Over Alleged Securities Fraud

The complaint centers on claims that Immutep violated the Securities Exchange Act by concealing the failure of its TACTI-004 trial for the drug eftilagimod alfa. Despite a January 30, 2026, SEC filing that touted strong progress, the company allegedly knew the trial would miss its primary efficacy endpoints. When the true nature of these results reached the market, shareholders suffered significant financial losses.

Shareholders who incurred losses during the specified class period have until July 6, 2026, to contact the firm and participate in the potential recovery. Brian Schall is managing inquiries at the Los Angeles office, where the firm is currently building the case for class certification. Until a court certifies the class, affected investors remain absent members and must take active steps to secure legal representation.